You are here

Medicare

CBO: Medicare negotiations will hamper drug development more than previously thought

CBO: Medicare negotiations will hamper drug development more than previously thought

Endpoints

drug development

Flag link:

With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment

With its Aduhelm proposal, Medicare is stepping into a heated debate about how best to improve equity in Alzheimer’s treatment

Stat

racial disparity

Alzheimer's disease

Flag link:

Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years

Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years

Endpoints

Alzheimer's disease

Flag link:

For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst

For Biogen's Aduhelm, narrow coverage from CMS 'could effectively spell the end': analyst

Fierce Pharma

clinical trials

Alzheimer's disease

Flag link:

Medicare proposes to limit coverage of Biogen Alzheimer's drug

Medicare proposes to limit coverage of Biogen Alzheimer's drug

BioPharma Dive

Flag link:

Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?

Biogen's Aduhelm faces a key coverage decision next week. Which way will Medicare rule, and how much does it matter?

Fierce Pharma

Alzheimer's disease

Flag link:

Biden touts drug cost measures in spending bill

Biden touts drug cost measures in spending bill

Beckers Hospital Review

Build Back Better Act

Flag link:

Exclusive accelerated approval drugs comprise ‘relatively small share’ of Medicare spending

Exclusive accelerated approval drugs comprise ‘relatively small share’ of Medicare spending

RAPS.org

accelerated approvals

Flag link:

Congress passes on delay to Medicare rate cuts for lab tests, for now

Congress passes on delay to Medicare rate cuts for lab tests, for now

Medtech Dive

Flag link:

Biden's Medicare drug price negotiations will leave pharma mostly unscathed: CBO

Biden's Medicare drug price negotiations will leave pharma mostly unscathed: CBO

Fierce Pharma

pharma industry

Build Back Better

Flag link:

Democrats’ major drug pricing reforms clear a hurdle in the House

Democrats’ major drug pricing reforms clear a hurdle in the House

Stat

Flag link:

MCIT breakthrough device payment pathway included in Cures 2.0 bill

MCIT breakthrough device payment pathway included in Cures 2.0 bill

Medtech Dive

breakthrough device

Flag link:

EU steers clear of Aduhelm as a bigger headache threatens

EU steers clear of Aduhelm as a bigger headache threatens

EP Vantage

Alzheimer's disease

Flag link:

Anticipating Aduhelm's costs, Medicare plans big jump in premiums

Anticipating Aduhelm's costs, Medicare plans big jump in premiums

BioPharma Dive

Alzheimer's disease

Flag link:

CMS scraps coverage rule for breakthrough devices

CMS scraps coverage rule for breakthrough devices

MedCity News

breakthrough device

Flag link:

Mixed court decisions for Novartis in DC and Sanofi, Novo Nordisk in NJ further complicate whose interpretation of 340B is correct

Mixed court decisions for Novartis in DC and Sanofi, Novo Nordisk in NJ further complicate whose interpretation of 340B is correct

Endpoints

Flag link:

Democrats' drug pricing deal is 'not a bad outcome' for pharma, analysts write

Democrats' drug pricing deal is 'not a bad outcome' for pharma, analysts write

Fierce Pharma

Flag link:

CMS reinstates Medicare's inpatient-only list in final rule, reversing Trump-era nix

CMS reinstates Medicare's inpatient-only list in final rule, reversing Trump-era nix

Medtech Dive

inpatient procedures

Flag link:

Dems close in on Medicare prescription drug negotiation compromise

Dems close in on Medicare prescription drug negotiation compromise

Politico

Flag link:

White House kills off major drug pricing reforms as Democrats fail to coalesce around Medicare negotiation plan

White House kills off major drug pricing reforms as Democrats fail to coalesce around Medicare negotiation plan

Endpoints

Flag link:

Pages